Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2006 1
2007 1
2009 1
2010 2
2011 5
2012 5
2013 4
2014 2
2015 3
2016 3
2017 3
2018 2
2019 4
2020 1
Text availability
Article attribute
Article type
Publication date

Search Results

36 results
Results by year
Filters applied: . Clear all
Page 1
The role of the ALK receptor in cancer biology.
Hallberg B, Palmer RH. Hallberg B, et al. Ann Oncol. 2016 Sep;27 Suppl 3:iii4-iii15. doi: 10.1093/annonc/mdw301. Ann Oncol. 2016. PMID: 27573755 Free article. Review.
This emphasises the need to tailor the sequence of ALK TKIs according to the ALK signature of each patient. Research into the oncogenic functions of ALK, and fast paced development of ALK inhibitors, has substantially improved outcomes for patients wit …
This emphasises the need to tailor the sequence of ALK TKIs according to the ALK signature of each patient. Research into the …
Targeting anaplastic lymphoma kinase in neuroblastoma.
Umapathy G, Mendoza-Garcia P, Hallberg B, Palmer RH. Umapathy G, et al. Among authors: hallberg b. APMIS. 2019 May;127(5):288-302. doi: 10.1111/apm.12940. Epub 2019 Apr 3. APMIS. 2019. PMID: 30803032 Free PMC article. Review.
ALK TKIs bind differently within the ATP-binding pocket of the ALK kinase domain and have been associated with different resistance mutations within ALK itself that arise in response to therapeutic use, particularly in ALK-fusion positive non-small cel
ALK TKIs bind differently within the ATP-binding pocket of the ALK kinase domain and have been associated with different resis
Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells.
Cervantes-Madrid D, Szydzik J, Lind DE, Borenäs M, Bemark M, Cui J, Palmer RH, Hallberg B. Cervantes-Madrid D, et al. Among authors: hallberg b. Sci Rep. 2019 Dec 18;9(1):19353. doi: 10.1038/s41598-019-55060-7. Sci Rep. 2019. PMID: 31852910 Free PMC article.
Continuous development of ALK inhibitors has resulted in the third generation inhibitor repotrectinib (TPX-0005), which targets the active kinase conformations of ALK, ROS1 and TRK receptors. ...PC12 cells transfected with different ALK mutant variants were u …
Continuous development of ALK inhibitors has resulted in the third generation inhibitor repotrectinib (TPX-0005), which targets the a …
Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib.
Guan J, Fransson S, Siaw JT, Treis D, Van den Eynden J, Chand D, Umapathy G, Ruuth K, Svenberg P, Wessman S, Shamikh A, Jacobsson H, Gordon L, Stenman J, Svensson PJ, Hansson M, Larsson E, Martinsson T, Palmer RH, Kogner P, Hallberg B. Guan J, et al. Among authors: hallberg b. Cold Spring Harb Mol Case Stud. 2018 Aug 1;4(4):a002550. doi: 10.1101/mcs.a002550. Print 2018 Aug. Cold Spring Harb Mol Case Stud. 2018. PMID: 29907598 Free PMC article.
Although mutations in ALK are heavily implicated in childhood neuroblastoma, response to the ALK TKI crizotinib has been disappointing. ...Pharmacological inhibition profiling of ALK-I1171T in response to various ALK TKIs identified an 11-fold improved …
Although mutations in ALK are heavily implicated in childhood neuroblastoma, response to the ALK TKI crizotinib has been disap …
Phosphoproteome and gene expression profiling of ALK inhibition in neuroblastoma cell lines reveals conserved oncogenic pathways.
Van den Eynden J, Umapathy G, Ashouri A, Cervantes-Madrid D, Szydzik J, Ruuth K, Koster J, Larsson E, Guan J, Palmer RH, Hallberg B. Van den Eynden J, et al. Among authors: hallberg b. Sci Signal. 2018 Nov 20;11(557):eaar5680. doi: 10.1126/scisignal.aar5680. Sci Signal. 2018. PMID: 30459281
ALK mutations have been identified in both familial and sporadic neuroblastoma cases as well as in 30 to 40% of relapses, which makes ALK a bona fide target in neuroblastoma therapy. Tyrosine kinase inhibitors (TKIs) that target ALK are currently in clinical
ALK mutations have been identified in both familial and sporadic neuroblastoma cases as well as in 30 to 40% of relapses, which makes
The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN.
Guan J, Tucker ER, Wan H, Chand D, Danielson LS, Ruuth K, El Wakil A, Witek B, Jamin Y, Umapathy G, Robinson SP, Johnson TW, Smeal T, Martinsson T, Chesler L, Palmer RH, Hallberg B. Guan J, et al. Among authors: hallberg b. Dis Model Mech. 2016 Sep 1;9(9):941-52. doi: 10.1242/dmm.024448. Epub 2016 Jul 7. Dis Model Mech. 2016. PMID: 27483357 Free PMC article.
The next-generation ALK inhibitor PF-06463922 is predicted to exhibit increased affinity for ALK mutants prevalent in neuroblastoma. We examined PF-06463922 activity in ALK-driven neuroblastoma models in vitro and in vivo In vitro kinase assays and cell-based …
The next-generation ALK inhibitor PF-06463922 is predicted to exhibit increased affinity for ALK mutants prevalent in neurobla …
MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.
Umapathy G, Guan J, Gustafsson DE, Javanmardi N, Cervantes-Madrid D, Djos A, Martinsson T, Palmer RH, Hallberg B. Umapathy G, et al. Among authors: hallberg b. Sci Signal. 2017 Nov 28;10(507):eaam7550. doi: 10.1126/scisignal.aam7550. Sci Signal. 2017. PMID: 29184034
Co-targeting ALK and the RAS-MAPK pathway is an attractive option, because monotherapies have not yet produced effective results in ALK-addicted neuroblastoma patients. ...In xenografts in mice, trametinib inhibited the growth of EML4-ALK-positive non-small c …
Co-targeting ALK and the RAS-MAPK pathway is an attractive option, because monotherapies have not yet produced effective results in …
Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells.
Alam MW, Borenäs M, Lind DE, Cervantes-Madrid D, Umapathy G, Palmer RH, Hallberg B. Alam MW, et al. Among authors: hallberg b. Front Oncol. 2019 Jul 5;9:579. doi: 10.3389/fonc.2019.00579. eCollection 2019. Front Oncol. 2019. PMID: 31334113 Free PMC article.
Initial clinical trial results have shown that it is difficult to inhibit growth of ALK positive neuroblastoma with crizotinib, motivating investigation of next generation ALK inhibitors with higher affinity for ALK. Here, alectinib, a potent next generation …
Initial clinical trial results have shown that it is difficult to inhibit growth of ALK positive neuroblastoma with crizotinib, motiv …
FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase.
Guan J, Umapathy G, Yamazaki Y, Wolfstetter G, Mendoza P, Pfeifer K, Mohammed A, Hugosson F, Zhang H, Hsu AW, Halenbeck R, Hallberg B, Palmer RH. Guan J, et al. Among authors: hallberg b. Elife. 2015 Sep 29;4:e09811. doi: 10.7554/eLife.09811. Elife. 2015. PMID: 26418745 Free PMC article.
Vertebrate ALK has been considered to be an orphan receptor and the identity of the ALK ligand(s) is a critical issue. Here we show that FAM150A and FAM150B are potent ligands for human ALK that bind to the extracellular domain of ALK and in addition t …
Vertebrate ALK has been considered to be an orphan receptor and the identity of the ALK ligand(s) is a critical issue. Here we …
Targeted Disruption of ALK Reveals a Potential Role in Hypogonadotropic Hypogonadism.
Witek B, El Wakil A, Nord C, Ahlgren U, Eriksson M, Vernersson-Lindahl E, Helland Å, Alexeyev OA, Hallberg B, Palmer RH. Witek B, et al. Among authors: hallberg b. PLoS One. 2015 May 8;10(5):e0123542. doi: 10.1371/journal.pone.0123542. eCollection 2015. PLoS One. 2015. PMID: 25955180 Free PMC article.
Mice lacking ALK activity have previously been reported to exhibit subtle behavioral phenotypes. In this study of ALK of loss of function mice we present data supporting a role for ALK in hypogonadotropic hypogonadism in male mice. ...These observations highl …
Mice lacking ALK activity have previously been reported to exhibit subtle behavioral phenotypes. In this study of ALK of loss …
36 results
Jump to page
Feedback